UTHR
United Therapeutics Corporation
489.40$
-1.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.7% | +68.1% | -26.3% | +64.2% | -126.5% | – | -20.8% | +34.2% | +21.9% | +35.7% | +17.6% | |
| – | +2.2% | -4.0% | -1.9% | +15.8% | +27.9% | +8.7% | +0.0% | +2.8% | +3.7% | +36.3% | +18.1% | |
| – | +47.4% | -95.7% | +507.4% | -135.9% | – | +260.8% | -15.4% | -22.9% | -63.4% | +268.3% | +2.6% | |
| – | -165.0% | – | +560.5% | -123.7% | – | +271.4% | +101.9% | -31.3% | – | – | – | |
| – | – | – | – | – | -243.3% | – | -376.1% | – | – | – | – | |
| – | +5.0% | -13.2% | +99.8% | +113.7% | -54.6% | -29.2% | +103.7% | +14.9% | +66.0% | +7.0% | +111.2% | |
| – | +48.8% | -90.4% | -1,830.0% | -1.8% | -59.1% | +120.2% | -34.1% | +66.7% | -11.3% | – | -232.1% | |
| – | -79.3% | -80.4% | -100.0% | – | – | +175.0% | – | – | +3.9% | – | – | |
| – | -18.3% | +26.7% | -50.0% | – | -110.8% | +76.2% | +191.9% | +5.6% | +21.1% | +7,234.8% | -1.2% | |
| – | -25.1% | -88.3% | – | -105.3% | – | -108.6% | -100.0% | – | +1,233.3% | +300.0% | -25.0% | |
| – | -22.5% | +11.3% | – | -85.5% | +9,601.6% | -102.8% | – | +68.3% | -115.8% | +10,444.5% | -8.4% | |
| – | +282.7% | -56.0% | -266.3% | – | – | -99.6% | +51,933.3% | -57.5% | +271.2% | +98.6% | -128.6% | |
| – | +8.2% | +80.3% | -35.4% | +53.1% | -148.9% | – | -31.4% | +39.0% | +12.6% | +44.5% | -3.7% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.